Toshio Iwasaki

Cellfree Sciences Co., Ltd. develops cell-free protein composition technology. The private company is based in Yokohama-shi, Japan.

R-Tech Ueno Ltd. engages in the research and development, manufacture and sale of pharmaceutical products. It operates through the following business divisions: New Pharmaceutical Research and Development, Pharmaceutical Manufacture and Sale, and Pharmaceutical Development Support and Contract Manufacturing Services. The New Pharmaceutical Research and Development business provides development for unmet medical needs area, orphan drug area, and anti-aging area. The Pharmaceutical Manufacture and Sale business handles the manufacture and sale of Rescula Eye Drops for glaucoma and ocular hypertension. The Pharmaceutical Development Support and Contract Manufacturing Services business covers the manufacture and sale of AMITIZA capsules for chronic idiopathic constipation. It also accepts contract manufacturing of eye drops, liquid drugs and liquid-filled hard capsules. The company was founded by Ryuji Ueno and Sachiko Kuno in September 1989 and is headquartered in Tokyo, Japan.

Mitsubishi UFJ Capital Co., Ltd. (MUCAP) is a venture capital subsidiary of Mitsubishi UFJ Financial Group, Inc. (TSE: 8306; NYSE: MTU), founded in 1974. The firm is headquartered in Tokyo with additional offices in Nagoya and Osaka.

Archetype Corp. provides business incubation and consulting services. It offers hands-on incubation services for seed-to-early startups. Its business activities include web sector consulting as well as startup business investment and training. The company was founded by Jun Nakajima and Osamu Higuchi on May 1, 2006 and is headquartered in Tokyo, Japan.

IC-VEC Ltd. is a biotechnology firm and do research and development for non-viral drug delivery systems. The company's therapeutic areas are cancer and liver diseases. IC-VEC plans to use its technology to develop DNA based and cancer vaccines. The company was founded in December 2001 by Andrew Miller and is headquartered in London, UK

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

ReqMed Co., Ltd. engages in drug development and consulting services. Its projects include development of pentosan polysulfate which alleviate pain symptoms of osteoarthritis, and eltoprazine which are used in the diseases such as attention-deficit hyperactivity disorder, cognitive impairment associated with schizophrenia and dyskinesia associated with Parkinson disease. The firm's clients include pharmaceutical and bio-pharmaceutical companies. The company was founded by Tadashi Matsumoto on May 12, 1998 and is headquartered in Machida, Japan.